VRTX

Vertex Pharmaceuticals Inc. - 2002 Annual Report (10-K) Summary

Business Context and Reporting Period

Company: Vertex Pharmaceuticals Incorporated
Reporting Period: Fiscal year ended December 31, 2002
Business Model: A global biotechnology company focused on discovering, developing, and commercializing novel small molecule drugs. The company operates two primary segments: Pharmaceuticals (drug discovery and development) and Discovery Tools and Services (assay development, screening, and instrumentation).
Key Products: The company's first commercial product is Agenerase (amprenavir), an HIV protease inhibitor co-promoted with GlaxoSmithKline (GSK). A second HIV drug, 908 (VX-175), had a New Drug Application (NDA) pending with the FDA as of year-end. The pipeline includes 15 drug candidates targeting viral diseases, inflammation, cancer, and genetic disorders.

Key Financial Metrics (Year Ended Dec 31, 2002)

Note: The filing does not provide a specific "profit margin" as the company is in a net loss position. Gross margins are not explicitly calculated in the summary text but revenue and cost components are detailed.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 4% to $161.1 million. This was driven by a 14% drop in Discovery Tools and Services revenue ($73.7M vs $87.4M in 2001) due to the completion of significant instrumentation projects and a strategic shift away from instrumentation sales. Pharmaceutical revenue increased slightly to $87.3 million, aided by a 12% increase in collaborative R&D revenue (primarily from Novartis).
• Increased R&D Spend: R&D expenses rose 35% to $203.0 million, reflecting increased investment in advancing the clinical pipeline (specifically p38 MAP kinase, IMPDH, HCV protease, and ICE inhibitors) and expanding research programs.
• Widened Net Loss: The net loss increased to $108.6 million from $66.2 million. The 2001 loss included a one-time gain of $10.3 million on the retirement of convertible notes and merger-related costs of $23.7 million, which were not present in 2002.
• Cash Position: Cash and marketable securities decreased by $108.2 million to $635.0 million, primarily due to operating losses and capital expenditures, offset by interest income.

Guidance, Outlook, and Risks

2003 Financial Guidance (Provided Feb 4, 2003):

• Pharmaceutical Revenue: Expected between $90 million and $105 million.
• Discovery Tools Revenue: Expected to be less than $10 million following the sale of PanVera assets.
• R&D Expenses: Projected between $215 million and $230 million.
• Net Loss: Expected between $140 million and $160 million (excluding a projected gain of >$75 million from the PanVera asset sale).
• Liquidity: Cash and securities expected to exceed $600 million at year-end 2003.

• Pipeline Progress: Management expects to select two priority drug candidates from the Vertex-driven portfolio for commercialization by the end of 2003. Key candidates include VX-148 (psoriasis), VX-702 (inflammatory diseases), and VX-950 (Hepatitis C).
• Partnerships: Critical to the business model. Key partners include Novartis (kinase inhibitors), GSK (HIV), Aventis (ICE inhibitors), and Serono (caspase inhibitors).
• Asset Sale: On March 28, 2003, the company completed the sale of certain PanVera LLC assets to Invitrogen for approximately $95 million, expecting a gain in excess of $75 million.

• Regulatory Approval: Success depends on FDA approval of 908 and other candidates. Delays or rejections could materially impact revenue.
• Collaboration Dependence: Partners (Novartis, GSK, Aventis) have termination rights. Termination could eliminate significant future revenue streams (e.g., up to $470 million from Novartis).
• Profitability: The company expects to incur losses for the foreseeable future and may need to raise additional capital.
• Legal Proceedings: Ongoing patent infringement suits with Chiron Corporation (Hepatitis C protease) and Oregon Health Sciences University (neurophilin patents).
• Debt: $315 million in 5% Convertible Subordinated Notes due September 2007.

Key Facts for Investor Verification

• 908 (VX-175) Approval Status: Verify the FDA's decision timeline for the NDA filed in December 2002, as this is a primary near-term revenue driver.
• PanVera Asset Sale Closing: Confirm the final net gain recognized from the March 28, 2003 sale to Invitrogen (expected >$75 million).
• Collaboration Milestones: Monitor progress on Phase II/III trials for partner-driven programs (e.g., pralnacasan with Aventis, 908 with GSK) to ensure milestone payments are triggered.
• Lease Obligations: Review the status of the 290,000 sq. ft. Kendall Square lease (payments commence May 2003), as management is exploring subleasing or exiting to minimize financial obligation.
• Legal Outcomes: Track the status of the Chiron and Oregon Health Sciences University litigation, as adverse outcomes could result in significant liabilities or loss of IP rights.